The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid.
The entry and persistence of phosphomycin in interstitial tissue fluid (ITF) were studied in 9 patients with normal renal function and 8 patients with varying degrees of renal impairment, all of whom received a single i.v. dose of 30 mg/kg. ITF was obtained from skin blisters produced by suction. The antibiotic followed a two-compartment open kinetic model. In patients with normal renal function, phosphomycin is incorporated rapidly into the ITF reaching a level of 60.4 micrograms/ml 60 min after administration. There was no statistically significant difference between the elimination rates from serum and ITF. The serum half-life of the slow disposition phase was 1.75 h in patients with normal renal function. There was a linear correlation between the elimination half-life of phosphomycin in serum and ITF in subjects with differing degrees of renal impairment.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism*; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D014511:Uremia / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D005578:Fosfomycin; D003404:Creatinine